264 related articles for article (PubMed ID: 20562124)
1. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation.
Vos R; Vanaudenaerde BM; Verleden SE; De Vleeschauwer SI; Willems-Widyastuti A; Van Raemdonck DE; Schoonis A; Nawrot TS; Dupont LJ; Verleden GM
Eur Respir J; 2011 Jan; 37(1):164-72. PubMed ID: 20562124
[TBL] [Abstract][Full Text] [Related]
2. Bronchiolitis obliterans syndrome and restrictive allograft syndrome: do risk factors differ?
Verleden SE; Ruttens D; Vandermeulen E; Vaneylen A; Dupont LJ; Van Raemdonck DE; Verleden GM; Vanaudenaerde BM; Vos R
Transplantation; 2013 May; 95(9):1167-72. PubMed ID: 23425818
[TBL] [Abstract][Full Text] [Related]
3. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome.
Verleden GM; Vanaudenaerde BM; Dupont LJ; Van Raemdonck DE
Am J Respir Crit Care Med; 2006 Sep; 174(5):566-70. PubMed ID: 16741151
[TBL] [Abstract][Full Text] [Related]
4. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial.
Ruttens D; Verleden SE; Demeyer H; Van Raemdonck DE; Yserbyt J; Dupont LJ; Vanaudenaerde BM; Vos R; Verleden GM
PLoS One; 2018; 13(4):e0193564. PubMed ID: 29624575
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation.
Verleden GM; Lievens Y; Dupont LJ; Van Raemdonck DE; De Vleeschauwer SI; Vos R; Vanaudenaerde BM
Transplant Proc; 2009 Jun; 41(5):1816-20. PubMed ID: 19545735
[TBL] [Abstract][Full Text] [Related]
6. Is it bronchiolitis obliterans syndrome or is it chronic rejection: a reappraisal?
Verleden GM; Dupont LJ; Van Raemdonck DE
Eur Respir J; 2005 Feb; 25(2):221-4. PubMed ID: 15684284
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory and immunomodulatory properties of azithromycin involved in treatment and prevention of chronic lung allograft rejection.
Vos R; Vanaudenaerde BM; Verleden SE; Ruttens D; Vaneylen A; Van Raemdonck DE; Dupont LJ; Verleden GM
Transplantation; 2012 Jul; 94(2):101-9. PubMed ID: 22461039
[TBL] [Abstract][Full Text] [Related]
8. Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection.
Federica M; Nadia S; Monica M; Alessandro C; Tiberio O; Francesco B; Mario V; Maria FA
Clin Transplant; 2011; 25(4):E381-9. PubMed ID: 21418327
[TBL] [Abstract][Full Text] [Related]
9. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome.
Yates B; Murphy DM; Forrest IA; Ward C; Rutherford RM; Fisher AJ; Lordan JL; Dark JH; Corris PA
Am J Respir Crit Care Med; 2005 Sep; 172(6):772-5. PubMed ID: 15976371
[TBL] [Abstract][Full Text] [Related]
10. Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation.
Gottlieb J; Szangolies J; Koehnlein T; Golpon H; Simon A; Welte T
Transplantation; 2008 Jan; 85(1):36-41. PubMed ID: 18192909
[TBL] [Abstract][Full Text] [Related]
11. Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT--a randomized double-blinded placebo-controlled study.
Lam DC; Lam B; Wong MK; Lu C; Au WY; Tse EW; Leung AY; Kwong YL; Liang RH; Lam WK; Ip MS; Lie AK
Bone Marrow Transplant; 2011 Dec; 46(12):1551-6. PubMed ID: 21317934
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation.
Treede H; Glanville AR; Klepetko W; Aboyoun C; Vettorazzi E; Lama R; Bravo C; Knoop C; Aubert JD; Reichenspurner H;
J Heart Lung Transplant; 2012 Aug; 31(8):797-804. PubMed ID: 22554673
[TBL] [Abstract][Full Text] [Related]
13. A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy.
Vanaudenaerde BM; Meyts I; Vos R; Geudens N; De Wever W; Verbeken EK; Van Raemdonck DE; Dupont LJ; Verleden GM
Eur Respir J; 2008 Oct; 32(4):832-43. PubMed ID: 18827151
[TBL] [Abstract][Full Text] [Related]
14. Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study.
Verleden GM; Verleden SE; Vos R; De Vleeschauwer SI; Dupont LJ; Van Raemdonck DE; Vanaudenaerde BM
Transpl Int; 2011 Jul; 24(7):651-6. PubMed ID: 21401732
[TBL] [Abstract][Full Text] [Related]
15. Post-transplant baseline FEV1 and the development of bronchiolitis obliterans syndrome: an important confounder?
Burton CM; Iversen M; Mortensen J; Carlsen J; Andersen CB; Milman N; Scheike T
J Heart Lung Transplant; 2007 Nov; 26(11):1127-34. PubMed ID: 18022078
[TBL] [Abstract][Full Text] [Related]
16. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis.
Gottlieb J; Mattner F; Weissbrodt H; Dierich M; Fuehner T; Strueber M; Simon A; Welte T
Respir Med; 2009 May; 103(5):743-9. PubMed ID: 19117741
[TBL] [Abstract][Full Text] [Related]
17. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.
Ailawadi G; Smith PW; Oka T; Wang H; Kozower BD; Daniel TM; Kron IL; Jones DR
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):594-602. PubMed ID: 18329476
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein in bronchoalveolar lavage fluid is associated with markers of airway inflammation after lung transplantation.
Vos R; Vanaudenaerde BM; De Vleeschauwer SI; Willems-Widyastuti A; Dupont LJ; Van Raemdonck DE; Verleden GM
Transplant Proc; 2009 Oct; 41(8):3409-13. PubMed ID: 19857759
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial.
Ruttens D; Verleden SE; Vandermeulen E; Bellon H; Vanaudenaerde BM; Somers J; Schoonis A; Schaevers V; Van Raemdonck DE; Neyrinck A; Dupont LJ; Yserbyt J; Verleden GM; Vos R
Am J Transplant; 2016 Jan; 16(1):254-61. PubMed ID: 26372728
[TBL] [Abstract][Full Text] [Related]
20. Acute cellular rejection is a risk factor for bronchiolitis obliterans syndrome independent of post-transplant baseline FEV1.
Burton CM; Iversen M; Carlsen J; Mortensen J; Andersen CB; Steinbrüchel D; Scheike T
J Heart Lung Transplant; 2009 Sep; 28(9):888-93. PubMed ID: 19716040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
